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ABSTRACT  
Introduction 
The irreversible EGFR inhibitors have demonstrated efficacy in NSCLC patients with 
activating EGFR mutations, but it is not known if they are superior to the reversible 
inhibitors.  Dacomitinib is an oral, small-molecule irreversible inhibitor of all 
enzymatically-active HER family tyrosine kinases. It has demonstrated promising efficacy 
in patients with an EGFR activating mutation. 
  
Methods 
The ARCHER 1009 (NCT01360554) and A7471028 (NCT00769067) studies randomized 
patients with locally advanced/metastatic NSCLC following progression with 1 or 2 prior 
chemotherapy regimens to dacomitinib or erlotinib. EGFR mutation testing was 
performed centrally on archived tumor samples. We pooled patients with common 
activating EGFR mutations from both studies to compare the efficacy of dacomitinib 
versus erlotinib. 
 
Results 
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121 patients with any EGFR mutation were enrolled to the two studies; 101 had 
activating mutations in exon 19 or 21.  For patients with exon19/21 mutations, the 
median progression-free survival per investigator’s review was 14.6 months (95%CI 9.0 
– 18.2) with dacomitinib and 9.6 months (95%CI 7.4 – 12.7) with erlotinib [unstratified 
HR 0.717 (95%CI 0.458 – 1.124) with 1-sided log-rank p=0.073]. The median survival was 
26.6 months (95% CI: 21.6-41.5) with dacomitinib vs. 23.2 months (95%CI: 16.0-31.8) 
with erlotinib, [unstratified HR 0.737 (95% CI: 0.431-1.259) with 1-sided log-rank 
p=0.132]. Dacomitinib was associated with a higher incidence of diarrhea and mucositis 
in both studies over erlotinib. 
 
Conclusions 
Dacomitinib has a favorable efficacy profile over erlotinib in patients with common 
activating EGFR mutations in this pooled subset analysis. An ongoing phase III study will 
compare dacomitinib to gefitinib in first-line therapy of patients with NSCLC harboring 
sensitizing EGFR mutations (ARCHER 1050; NCT01774721). 
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INTRODUCTION 
Mutations in the epidermal growth factor receptor (EGFR) gene are present in 
approximately 15% of Caucasian and 30–40% of Asian patients with advanced lung 
adenocarcinoma.1 The EGFR tyrosine kinase inhibitors (TKIs) erlotinib and gefitinib have 
demonstrated robust response rates and progression-free survival (PFS) in this 
molecularly defined subgroup of patients.2, 3 Among the EGFR mutations, exon 19 
deletions and point mutations in exon 21 are associated with sensitivity to EGFR TKIs, 
whereas insertion mutations in exon 20 are specifically associated with resistance to 
EGFR TKIs.4, 5 
 
Dacomitinib (PF-00299804; Pfizer Inc., New York, NY, USA) is an orally bioavailable, 
small-molecule covalent binding inhibitor of all enzymatically active HER family tyrosine 
kinases (EGFR, HER2, HER4).6 Of note, dacomitinib has demonstrated superior activity 
versus reversible EGFR TKIs in gefitinib- and erlotinib-sensitive and -resistant preclinical 
models.6, 7 In a randomized phase II study of an unselected population with advanced 
non-small cell lung cancer (NSCLC), dacomitinib showed improved PFS compared with 
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erlotinib in the second-/third-line setting, with a hazard ratio (HR) of 0.66 (95% 
confidence interval [CI], 0.47–0.91; 2-sided p = 0.01).8 This led to a phase III study of 
dacomitinib versus erlotinib in patients with advanced NSCLC (ARCHER 1009).9 The co-
primary objectives were to compare the PFS in the overall patient population and in 
those with wild-type KRAS mutation. There was no improvement in PFS or OS for 
dacomitinib over erlotinib in either of the two patient populations.  
 
Afatinib, another irreversible EGFR inhibitor, has been studied extensively in patients 
with EGFR mutations. In randomized studies, afatinib is associated with superior PFS 
over platinum-based combination chemotherapy in this patient population.10 A pooled 
analysis of results from two randomized studies of afatinib demonstrated improvement 
in overall survival over chemotherapy for patients with EGFR exon 19 deletion mutation, 
but the benefit was not observed for those with exon 21 point mutation.11  It is 
noteworthy that none of the clinical trials that compared an EGFR TKI to chemotherapy 
has demonstrated a survival advantage in patients with EGFR mutation, presumably 
related to crossover of patients on the control arm for later lines of therapy.  
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The observations of a superior pre-clinical efficacy profile with irreversible pan-HER 
inhibitors over first-generation selective reversible EGFR TKIs such as erlotinib and 
gefitinib in NSCLC models, and the promising clinical activity in advanced NSCLC calls for 
direct comparisons of the two classes of compounds in NSCLC patients with EGFR 
mutation. Here, we report a subgroup analysis for patients with EGFR mutation included 
in two  randomized studies that compared  dacomitinib to erlotinib. 
 
METHODS 
This analysis was performed to evaluate the safety and efficacy of dacomitinib in NSCLC 
patients with common EGFR activating mutations.  Data from 2 studies were used for 
this analysis: 
 ARCHER 1009: A multinational, randomized, double-blinded, double dummy 
phase III study in 2nd/3rd line NSCLC.  
 A7471028: A multinational, randomized, open-label phase II study in 2nd/3rd line 
NSCLC. 
The two studies had similar design except one was double-blinded and the other was 
open-label. Both studies enrolled adults with pathologically confirmed advanced 
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measureable NSCLC who had available archived or recently obtained tumor specimen, a 
performance status of 0-2 on the Eastern Cooperative Oncology Group (ECOG) scale, 
adequate renal, hepatic and hematologic function, and previous therapy with one or 
two systemic regimens. All patients provided written, informed consent prior to study 
enrollment. 
 
Patients were randomized 1:1 to receive dacomitinib 45mg daily or erlotinib 150 mg 
daily stratified by smoking status (non- versus ever-smoker), race (Asian versus non-
Asian), and histology (adenocarcinoma versus non-adenocarcinoma) for both studies.  In 
addition, performance status (0/1 vs. 2) was also included as one stratification factor for 
ARCHER 1009.  In the A7471028 study, antitumor activity was assessed at baseline, the 
end of cycles 2–6, and every other cycle thereafter according to RECIST V1.0. Toxicities 
were graded by National Cancer Institute Common Terminology Criteria for Adverse 
Events, version 3.0.1. The ARCHER 1009 participants underwent tumor assessments at 
baseline, end of cycles 2, 3 and 4, followed by every other cycle thereafter according to 
RECIST V1.1.  Toxicities were graded by National Cancer Institute Common Terminology 
Criteria version 4.0.3. 
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Based on the similarity between the two studies, we combined the data from the two 
studies for the pooled analyses in the subgroup of patients who had EGFR mutant NSCLC 
and that of patients who had activating EGFR mutation in exon 19 or 21. Common study 
endpoints reported included the progression-free survival based on investigator’s 
review (defined as the time from randomization to the date of disease progression or 
death, whichever occurred first), objective response rate (defined as proportion of 
patients achieving a complete response or partial response out of the ITT population), 
duration of response (defined as the time of the first documentation of response to the 
date of disease progression), overall survival (defined as the time from randomization to 
the date of death from any cause), and safety profiles. The information presented 
reflects information in the ARCHER 1009 database as of 31 JUL 2014 and A7471028 
database as of 13 OCT 2014. EGFR mutational analysis was performed utilizing a 
Scorpion ARMs PCR assay (Qiagen) as well as PCR/bidirectional sequencing (Genzyme 
Genetics/LabCorp). 
  
As this was an exploratory analysis, no multiplicity adjustment was applied and p-values 
were provided for descriptive purpose only. Time-to-event endpoints were analysed 
using the Kaplan-Meier method, log-rank test and cox proportional hazard model.  The 
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binary endpoints were analysed using exact methods. Given the small sample size, only 
the unstratified analyses were reported. EGFR mutant patients who were randomized to 
either of the two studies were included for the analysis of baseline characteristics and 
efficacy (the ITT population).  EGFR mutant patients who received at least one dose of 
study medication were included for the safety analyses.  Similarly, the analyses for the 
subgroup of patients with activating EGFR mutation in exon 19 or 21 were conducted. 
SAS version 9.1.3 was used for all statistical analyses.  
 
RESULTS 
Patient Characteristics and Disposition 
The A7471028 study enrolled a total of 188 patients between November 2008 and 
October 2009, to dacomitinib (n = 94) or erlotinib (n = 94); The ARCHER 1009 study 
enrolled 878 patients between June 2011 and March 2013 with equal distribution 
between the dacomitinib and erlotinib arms.  
  
A total of 121 patients had EGFR mutations in the pooled database, out of which 101 
had activating mutations in exon 19 or 21 (Table 1). Dacomitinib was administered to 52 
patients and erlotinib to 48. One patient with EGFR mutation in exon 19 was 
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randomized to dacomitinib, but did not receive study therapy. As expected, there were 
more female patients, Asians, and never-smokers in the EGFR mutant sub-groups 
compared to the overall study population.  
 
Among patients with activating EGFR mutations, the distribution of males and females 
were comparable between dacomitinib and erlotinib. The median age was 60 yrs and 62 
yrs respectively for dacomitinib and erlotinib. The dacomitinib group had a slightly 
higher proportion of Asians (56.6% vs. 47.9%) than on the erlotinib group. There were a 
higher proportion of patients with exon 19 mutation on the erlotinib group (75% vs. 
60.4%), whereas the exon 21 mutation was overrepresented in the dacomitinib group . 
 
Efficacy  
 The median progression-free survival was 10.9 months (95% CI: 7.4-17.4) vs. 9.6 
months (95% CI: 7.4-11.3) with erlotinib [HR 0.815, 95% CI 0.542-1.224, 1-sided log-rank 
P of 0.160] (Figure 1A). The overall survival was similar between dacomitinib and 
erlotinib. The median overall survival was 26.6 months (95% CI 20.1-29.0) with 
dacomitinib and 24.1 months (95%CI 17.9-39.4) with erlotinib. The hazard ratio was 
0.958 (95% CI 0.596-1.538) and 1-sided p-value from log rank test was 0.431 (Figure 1B). 
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For patients with activating EGFR mutations, the median progression-free survival was 
14.6 months (95%CI 9.0 – 18.2) for dacomitinib and 9.6 months (95%CI 7.4 – 12.7) for 
erlotinib (HR 0.717, 95%CI 0.458 – 1.124, 1-sided log-rank p=0.073) (Figure 2A). The 
median overall survival was 26.6 months (95%CI 21.6 – 41.5) for dacomitinib and 23.2 
months (95%CI 16.0 – 31.8) for erlotinib (HR 0.737, 95%CI 0.431 – 1.259,1-sided log-rank 
p=0.132) (Figure 2B). The corresponding pooled analyses were conducted separately in 
exon 19 and exon 21. 
 
For patients with exon 19 mutations, the estimate of median progression-free survival 
was 14.6 months (95% CI: 9.2-20.6) with dacomitinib and 10.0 months (95% CI: 7.2-12.8) 
with erlotinib.  The hazard ratio for progression-free survival favored dacomitinib with a 
hazard ratio of 0.585 (95% CI 0.335-1.024, 1-sided log-rank P = 0.029) (Figure 3A). This 
translated to a hazard ratio of 0.719 (95% CI 0.366-1.412) for overall survival (1-sided 
log-rank P=0.169) with median survival 26.6 months (95% CI: 20.3-52.5) in dacomitnib 
arm vs. 24.2 (95% CI: 15.7-39.4) in erlotinib arm. However, among patients with exon 21 
mutations, the estimate of median progression-free survival was 10.0 months (95% CI: 
4.2-19.6) with dacomitnib and 9.0 months (95% CI: 1.0-27.7) with erlotinib. There was 
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no significant improvement in progression-free survival for dacomitinib with a hazard 
ratio of 0.955 (95% CI 0.421-2.168) (1-sided log-rank P=0.458) (Figure 3B). The median 
survival was 26.9 months (95% CI: 9.9-41.5) with dacomitnib and 19.8 months (95% CI: 
3.1-31.7) with erlotinib.  The hazard ratio for overall survival was 0.688 (95% CI 0.276-
1.717) with a 1-sided P of 0.21. 
 
The objective response rate is similar between the two treatment arms in the above 
patient populations.  Among the 121 EGFR mutant patients, there were 2 patients 
achieving a complete response and 39 patients achieving a partial response in 
dacomitinib arm (ORR: 62.1% with 95% CI 49.3%-73.8%); and there were 3 complete 
responses and 30 partial responses in erlotinib arm (ORR: 60.0% with 95% CI 45.9%-
73.0%).  Among the 101 patients with common activating EGFR mutation, the ORR was 
67.9% (95% CI: 53.7%-80.1%) in dacomitinib arm and 64.6% (95% CI: 49.5%-77.8%) in 
erlotinib arm.   For patients with mutation in exon 19, the rate was slightly higher in 
dacomitinib arm: 75.0% (95% CI: 56.6%-88.5%) with dacomitinib vs. 63.9% (95% CI: 
46.2%-79.2%) with erlotinib.  Among patients with mutation in exon 21, the response 
rate was 57.1% (95% CI 34.0%-78.2%) with dacomitnib vs. 66.7% (95% CI 34.9%-90.1%) 
with erlotinib.  
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Safety and Tolerability 
 
In total, there were 120 patients with EGFR mutations included in the safety analysis, 65 
were treated with dacomitnib and 55 were treated with erltoinib. Median duration of 
treatment for the  patients who received dacomitinib was 11.0 months (IQR: 3.7-19.4 
months) and the median duration for the 55 patients who were treated with erlotinib 
was 9.6 months (IQR: 3.7-16.8 months).   The EGFR mutation subgroup and common 
EGFR activating mutation subgroup had a similar toxicity profile to the overall patient 
population. As in the all-patient population in ARCHER 1009, diarrhoea, stomatitis, 
paronychia, and mucosal inflammation were observed more frequently in patients 
treated with dacomitinib compared with patients treated with erlotinib.  The most 
common observed treatment-related adverse events in patients with EGFR mutations 
treated with dacomintib were diarrhea (86.2%), paronychia (56.9%), stomatitis (56.9%), 
dermatitis acneiform (41.5%), rash (36.9%), and dry skin (33.8%). There were 70 deaths 
among the 120 patients with EGFR mutations at the data cut-off dates, none of them 
were treatment-related.    
 
Post-study treatments 
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For patients with activating mutations, post-study treatments were administered to 44% 
of patients on the dacomitinib arm compared to 52% on the erlotinib arm. The median 
number of post-study treatments on both groups was 2. Subjects received a median of 
69 weeks and 50 weeks of post-study treatments on the dacomitinib and erlotinib 
groups respectively. The most commonly used post-study treatment agents were 
docetaxel, erlotinib, gefitinib and pemetrexed. Post-study treatment with an EGFR 
inhibitor was given to 17% and 27% of patients on the dacomitinib and erlotinib groups 
respectively.  
  
DISCUSSION 
 
The availability of data from two nearly identical randomized studies that compared 
dacomitinib to erlotinib in patients with advanced NSCLC prompted this analysis to 
evaluate outcomes for patients with EGFR activating mutation. Presently, with the FDA 
approval of both first and second-generation EGFR inhibitors, there is a need for 
randomized data to make treatment decisions regarding the most efficacious first-line 
EGFR TKI therapy.  
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Our analysis demonstrated favorable trends with dacomitinib over erlotinib for the 
EGFR activation mutation patient sub-group. This is in contrast to the overall result of 
ARCHER 1009 study that failed to demonstrate an efficacy advantage with dacomitinib 
over erlotinib in an unselected population. While our analysis is subject to the 
limitations of post-hoc analyses of this type, it is noteworthy that the ARCHER 1009 had 
a pre-planned analysis for the EGFR mutation sub-group of patients. Another notable 
strength of this study is the fact that the mutation testing was performed centrally. 
There were no substantial differences in the receipt of post-study treatments between 
the two groups to account for the differences in efficacy.  
 
Dacomitinib has been investigated for the treatment of patients with EGFR mutant 
NSCLC in a single-arm, phase II study of first-line treatment that demonstrated an 
objective response rate of 76% and median PFS of 18.2 months among 45 patients with 
sensitizing mutations (95% CI, 12.8–23.8).12 The median survival for this group of 
patients was approximately 40 months. In contemporary studies with the reversible 
first-generation compounds, the median PFS in EGFR mutated tumors is approximately 
9–11 months. Afatinib was associated with a median PFS of approximately 13 months in 
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patients with sensitizing EGFR mutation in a phase III trial.10 Furthermore, the efficacy 
with afatinib was greater in patients with exon 19 deletion EGFR mutation relative to 
chemotherapy, and was associated with improved overall survival in a recent meta-
analysis.11 In contrast, patients with an exon 21 mutation did not appear to derive 
survival benefit from afatinib. These results are substantiated by our analysis, which 
demonstrated a favorable progression-free survival with dacomitinib in patients with 
exon 19, but not in those with exon 21 mutations. These data raise the possibility that 
the differential sensitivity to reversible and irreversible EGFR inhibitors might be 
dependent on the specific mutation.  
 
All of these lines of evidence, combined with supportive preclinical data, indicate 
that the irreversible inhibitors might be associated with a favorable efficacy profile 
in patients with the common activating EGFR mutations. However, prospective 
comparison in randomized clinical trials is needed to address this important clinical 
issue. As such, a phase III study of dacomitinib compared with gefitinib in patients 
with sensitizing mutations is underway (ARCHER 1050; NCT01774721).13 
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There are no standard treatment options for patients who develop secondary resistance 
to EGFR TKI therapy, though promising new agents such as rociletinib and AZD9291 are 
in clinical trials14, 15. Approaches to delay the emergence of resistance have become a 
major focus of investigations for patients with activating EGFR mutations. The mutation-
specific EGFR inhibitors are also being compared directly to first generation EGFR TKIs 
for first line therapy in ongoing studies.  The positive results of a Japanese study that 
compared the combination of bevacizumab with erlotinib to erlotinib alone provide 
another promising approach to treat patients with EGFR activating mutations.16 The 
relative roles of dacomitinib and afatinib will be important to understand, so that they 
can be appropriately utilized in the treatment algorithm for advanced NSCLC. 
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TABLE 1. Patient Baseline Characteristics 
 
Patients Characteristics 
 Pooled EGFR Mutant Pooled Common Activating 
EGFR Mutant 
Dacomitinib 
(N=66) 
Erlotinib 
(N=55) 
Dacomitinib 
(N=53) 
Erlotinib 
(N=48) 
Safety Analysis Set: 
[n(%)] 
65 (98.5) 55 (100) 52 (98.1) 48 (100) 
Age (years)     
Median (Range) 61 (32-84) 62 (34-79) 60 (32-82) 62 (34-79) 
<65 40 (60.6) 35 (63.6) 35 (66.0) 30 (62.5) 
>=65 27 (39.4) 20 (36.4) 18 (34.0) 18 (37.5) 
Gender [n(%)]     
     Male 33 (50.0) 28 (50.9) 27 (50.9) 24 (50.0) 
     Female 33 (50.0) 27 (49.1) 26 (49.1) 24 (50.0) 
Race [n(%)]     
     White 30 (45.5) 27 (49.1) 23 (43.4) 23 (47.9) 
     Black 1 (1.5) 0 0 0 
     Asian 35 (53.0) 26 (47.3) 30 (56.6) 23 (47.9) 
     Other 0 2 (3.6) 0 2 (4.2) 
ECOG Performance 
Status [n(%)] 
  
  
     0 22 (33.3) 27 (49.1) 18 (34.0) 21 (43.8) 
     1 34 (51.5) 24 (43.6) 28 (52.8) 23 (47.9) 
     2 10 (15.2) 4 (7.3) 7 (13.2) 4 (8.3) 
Histology [n(%)]     
     Adenocarcinoma 45 (68.2) 41 (74.5) 36 (67.9) 36 (75.0) 
     Squamous Cell 
Carcinoma 
21 (31.8) 14 (25.5) 17 (32.1) 12 (25.0) 
     Large Cell 
     Other 
Smoking Status 
[n(%)] 
  
  
     Never Smoker 31 (47.0) 28 (50.9) 26 (49.1) 24 (50.0) 
     Smoker 35 (53.0) 27 (49.1) 27 (50.9) 24 (50.0) 
Current Stage [n(%)]     
     Stage III, IIIA, IIIB 5 (7.6) 3 (5.5) 3 (5.7) 2 (4.2) 
      Stage IV  61 (92.4) 52 (94.5) 50 (94.3) 46 (95.8) 
      Unknown/Not 0 0 0 0 
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Reported 
EGFR Status [n(%)]*     
     Wild Type 0 0 0 0 
     Mutant 66 (100) 55 (100) 53 (100) 48 (100) 
         Activating 57 (86.4) 52 (94.5) 53 (100) 48 (100) 
             Exon 18 4 (6.1) 4 (7.3) 0 0 
             Exon 19 32 (48.5) 36 (65.5) 32 (60.4) 36 (75.0) 
             Exon 21 21 (31.8) 12 (21.8) 21 (39.6) 12 (25.0) 
         Non-activating* 8 (12.1) 2 (3.6) 0 0 
         Unknown 
Significance** 
1 (1.5) 1 (1.8) 0 0 
     Unknown/Not 
Done 
0 0 0 0 
*Non-activating EGFR mutation including patients with EGFR mutation in exon, exon 
19+T790M or exon 21+T790M.  
**Unknown significance with EGFR mutation means EGFR mutation in both exon 18 and 
exon 21.  
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Figures 
 
1A: Kaplan-Meier curve for PFS for patients with EGFR mutation 
1B: Kaplan-Meier curve for OS for patients with EGFR mutation 
2A: Kaplan-Meier curve for PFS for patients with activating EGFR mutation 
2B: Kaplan-Meier curve for OS for patients with activating EGFR mutation  
3A: Kaplan-Meier curve for PFS for patients with EGFR exon 19 mutation 
3B: Kaplan-Meier curve for PFS for patients with EGFR exon 21 mutation 
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